Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Bexsero regulatory update

March 3, 2014 8:00 AM UTC

Novartis said FDA approved an extended treatment IND from the U.S. Centers for Disease Control to use Bexsero to combat an outbreak of meningococcal disease caused by Neisseria meningitides serogroup B at the University of California, Santa Barbara, which has had 4 confirmed cases of the disease since November. The vaccination program at UCSB began Feb. 24 and will end March 7. Last November, FDA approved use of Bexsero in response in an outbreak of meningococcal disease at Princeton University (see BioCentury, Nov. 25, 2013). ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article